Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of YN001 in adults with coronary atherosclerosis
CTR20261147Phase 2Active
- Sponsor
- Innomed
- Start
- Aug 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of YN001 in coronary arteriosclerosis, atherosclerotic disease, sponsored by Innomed. Started Aug 2026; status: active.
02
Drugs
YN001
03
Conditions
coronary arteriosclerosisatherosclerotic disease
Beyond the preview
Go deeper on CTR20261147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261147.